PRGO - Perrigo Company plc

NYSE - NYSE Delayed Price. Currency in USD
46.34
-1.43 (-2.99%)
At close: 4:02PM EDT
Stock chart is not supported by your current browser
Previous Close47.77
Open47.59
Bid46.39 x 800
Ask46.40 x 1200
Day's Range46.21 - 47.87
52 Week Range36.28 - 78.90
Volume969,883
Avg. Volume1,244,600
Market Cap6.305B
Beta (3Y Monthly)1.94
PE Ratio (TTM)72.52
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield0.84 (1.76%)
Ex-Dividend Date2019-08-29
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • Perrigo To Present At Upcoming Investor Conferences
    PR Newswire

    Perrigo To Present At Upcoming Investor Conferences

    TASE: PRGO), today announced that CEO and President, Murray S. Kessler and CFO, Ray Silcock, will host one-on-one meetings at the Barclay's Global Consumer Staples Conference on September 5, 2019 in Boston. TASE: PRGO) is dedicated to making lives better by bringing "Quality, Affordable Self-care Products™" that consumers trust everywhere they are sold. The Company is a leading provider of over-the-counter health and wellness solutions that enhance individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed. Visit Perrigo online at http://www.perrigo.com. Certain statements in this press release are "forward-looking statements." These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements.

  • Perrigo Announces Patent Litigation Settlement for the Generic Version of Nascobal® Nasal Spray
    PR Newswire

    Perrigo Announces Patent Litigation Settlement for the Generic Version of Nascobal® Nasal Spray

    Perrigo Executive Vice President and President Rx Pharmaceuticals Sharon Kochan stated, "This settlement is another example of our long-term commitment and investments in our extended topicals strategy. TASE: PRGO) is dedicated to making lives better by bringing "Quality, Affordable Self-care Products™" that consumers trust everywhere they are sold. The Company is a leading provider of over-the-counter health and wellness solutions that enhance individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed. Visit Perrigo online at http://www.perrigo.com. Certain statements in this press release are "forward-looking statements." These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements.

  • Perrigo Company plc Reports Second Quarter 2019 Financial Results, Reaffirms Outlook, Progresses Consumer Transformation
    PR Newswire

    Perrigo Company plc Reports Second Quarter 2019 Financial Results, Reaffirms Outlook, Progresses Consumer Transformation

    DUBLIN , Aug. 8, 2019 /PRNewswire/ -- GAAP ("reported") net sales were $1.15 billion , reflecting a 3% decline versus the prior year period. Non-GAAP ("adjusted") net sales increased ...

  • PR Newswire

    Perrigo Announces Resignation Of Jeffrey C. Smith From Its Board Of Directors

    TASE: PRGO), a leading provider of "Quality Affordable Self-Care Products™", today announced that Jeffrey C. Smith, Managing Member, Chief Executive Officer, and Chief Investment Officer of Starboard Value LP, who has been a director since 2017, has resigned from Perrigo's Board of Directors effective August 7, 2019. "It is with mixed emotions that I leave the Board of Directors of Perrigo. "We are fortunate to have recruited a world-class leader in Murray Kessler who has quickly assembled an outstanding management team and repositioned Perrigo as a leading self-care company with numerous opportunities for growth and improved efficiency.

  • Perrigo Announces Quarterly Dividend
    PR Newswire

    Perrigo Announces Quarterly Dividend

    TASE: PRGO) is dedicated to making lives better by bringing "Quality, Affordable Self-care Products™" that consumers trust everywhere they are sold. The Company is a leading provider of over-the-counter health and wellness solutions that enhance individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed. Visit Perrigo online at (http://www.perrigo.com). Certain statements in this press release are "forward-looking statements." These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements.

  • Perrigo Announces Second Quarter Calendar Year 2019 Earnings Date
    PR Newswire

    Perrigo Announces Second Quarter Calendar Year 2019 Earnings Date

    TASE: PRGO), today announced that it will release its second quarter calendar year 2019 financial results on Thursday, August 8, 2019. The Company will host a conference call beginning at 8 a.m. (EDT).

  • Perrigo Completes Divestiture of Animal Health Business for $185 Million
    PR Newswire

    Perrigo Completes Divestiture of Animal Health Business for $185 Million

    TASE: PRGO) today announced that it has completed the previously announced divestiture of its Animal Health business to PetIQ (PETQ) for $185 million. Perrigo CEO and President Murray S. Kessler stated, "Completing the divestiture of the Animal Health business is an important step in the transformation of Perrigo into a consumer-focused self-care company.

  • GlobeNewswire

    PetIQ, Inc. Completes Acquisition of Perrigo Animal Health

    EAGLE, Idaho, July 08, 2019 -- PetIQ, Inc. (“PetIQ” or the “Company”) (Nasdaq: PETQ), a leading pet medication and wellness company, today announced effective today, it has.

  • Perrigo Announces FDA Final Approval and Launch Of The AB-rated Generic Version Of Metrogel-Vaginal® Gel
    PR Newswire

    Perrigo Announces FDA Final Approval and Launch Of The AB-rated Generic Version Of Metrogel-Vaginal® Gel

    TASE: PRGO) today announced its product development partner received final approval from the U.S. Food and Drug Administration for its AB-rated Abbreviated New Drug Application ("ANDA") referencing Metrogel-Vaginal® (metronidazole vaginal gel 0.75%).  Perrigo will acquire full ownership of the ANDA under a pre-existing arrangement with its partner within 30 days and anticipates launching this product immediately thereafter. The product is manufactured by Perrigo and was developed through its partnership with Capstone Development Solutions, a company of Water Street Healthcare Partners, a strategic investor focused exclusively on the health care industry. Perrigo Executive Vice President and President Rx Pharmaceuticals, Sharon Kochan stated, "This launch exemplifies Perrigo's commitment to developing and launching products within the extended topicals category.

  • PR Newswire

    Perrigo Completes Acquisition Of Ranir, Raises Guidance

    - Advances transformation to a consumer-focused, self-care company - Raises 2019 non-GAAP ("adjusted") diluted EPS guidance to between $3.75 - $4.05 (1), which includes accretion of $0.10 from ...

  • GlobeNewswire

    Sol-Gel Technologies Announces Seventh Agreement for Generic Product Candidates with Perrigo

    Consistent with Sol-Gel’s prior agreements with Perrigo, Perrigo will seek regulatory approval with the U.S. Food and Drug Administration (“FDA”) for these generic product candidates. If approved by the FDA, Perrigo has agreed to commercialize the generic product candidates in the United States.

  • PR Newswire

    INVESTOR ALERT: Monteverde & Associates PC Launches Legal Inquiry Regarding the Acquisition

    NEW YORK , May 22, 2019 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York ...

  • Perrigo Announces FDA Final Approval For AB Rated Generic Version Of Voltaren® Gel 1%
    PR Newswire

    Perrigo Announces FDA Final Approval For AB Rated Generic Version Of Voltaren® Gel 1%

    TASE: PRGO) today announced its partner received final approval from the U.S. Food and Drug Administration for its AB rated Abbreviated New Drug Application (ANDA) referencing Voltaren® Gel, 1% (diclofenac sodium topical gel, 1%). Perrigo will acquire full ownership of the ANDA under a pre-existing arrangement with its partner within 30 days. Perrigo will manufacture diclofenac sodium topical gel 1% in its plant in Israel.

  • Perrigo Unveils Self-Care Transformation Plan, 2019 Guidance And Long-Term Growth Targets At Investor Day
    PR Newswire

    Perrigo Unveils Self-Care Transformation Plan, 2019 Guidance And Long-Term Growth Targets At Investor Day

    Chief Executive Officer and President Murray S. Kessler, along with several key members of his leadership team, will share the Company's strategic plan, vision, and financial objectives while introducing their priorities for transforming Perrigo from a healthcare company to a consumer self-care company. Kessler commented, "We have begun the process of transformation to recapture what we call 'The Perrigo Advantage'. The team has been hard at work during my first six months as CEO, analyzing our challenges and most importantly, building actionable plans to reinvent the company.

  • PR Newswire

    Global Oral Care Leader Ranir® Agrees to be Acquired by Leading Global Self-Care Company Perrigo

    Combines Two Consumer-Focused Self-Care Companies Dedicated to Meeting Customer Needs; Expands Ability to Deliver Millions of Affordable Healthy Smiles Worldwide GRAND RAPIDS, Mich. , May 9, 2019 /PRNewswire/ ...

  • Perrigo To Expand Into Adjacent Self-Care Category By Acquiring Ranir Global Holdings LLC, The Leading Global Private Label Supplier Of Oral Self-Care Products
    PR Newswire

    Perrigo To Expand Into Adjacent Self-Care Category By Acquiring Ranir Global Holdings LLC, The Leading Global Private Label Supplier Of Oral Self-Care Products

    DUBLIN, May 9, 2019 /PRNewswire/ -- Perrigo Company plc (NYSE, TASE: PRGO) today announced that it has reached a definitive agreement to purchase privately-held Ranir Global Holdings LLC ("Ranir") in a transaction valued at $750 million on a cash-free, debt-free basis, or approximately $685 million net of cash tax benefits on a present value basis. Ranir is the largest private label oral care company globally, with a comprehensive portfolio of 300+ highly customized oral care solutions including power toothbrush heads, power toothbrush handles, whitening strips, manual toothbrushes, floss, dentures and travel kits that it sells into over 50 countries worldwide.

  • Perrigo Company plc Reports First Quarter 2019 Financial Results, Begins Consumer Self-Care Transformation
    PR Newswire

    Perrigo Company plc Reports First Quarter 2019 Financial Results, Begins Consumer Self-Care Transformation

    DUBLIN , May 8, 2019 /PRNewswire/ --  GAAP ("reported") net sales were $1.2 billion , reflecting a 4% decline versus the prior year period, or down 1% excluding the unfavorable impact of currency. ...

  • Perrigo To Divest Animal Health Business For $185 Million In Cash As Part Of Consumer Self-Care Transformation
    PR Newswire

    Perrigo To Divest Animal Health Business For $185 Million In Cash As Part Of Consumer Self-Care Transformation

    TASE: PRGO), today announced that it has reached a definitive agreement to sell its Animal Health business to PetIQ (PETQ) in a transaction valued at $185 million in cash. Perrigo CEO and President Murray S. Kessler commented, "We are pleased to have reached an agreement with PetIQ on selling our Animal Health business and look forward to working with them to ensure a seamless transition. In calendar year 2018, Perrigo realized $94 million in net sales and $0.08 of adjusted diluted EPS from the Animal Health business.

  • GlobeNewswire

    PetIQ, Inc. Reports Record First Quarter 2019 Financial Results

    First Quarter 2019 Net Sales Increased 29% Year-Over-Year to $148.4 MillionReiterates Full Year 2019 Outlook Enters Into Definitive Agreement to Acquire Perrigo Animal Health.

  • Perrigo Announces First Quarter Calendar Year 2019 Earnings Date And Upcoming Conference Participation
    PR Newswire

    Perrigo Announces First Quarter Calendar Year 2019 Earnings Date And Upcoming Conference Participation

    TASE: PRGO), today announced that it will release its first quarter calendar year 2019 financial results on May 8, 2019 after market close in the U.S. and will discuss the results and 2019 guidance at its Investor Day on May 9, 2019. The company also announced that Perrigo President and Chief Executive Officer, Murray S. Kessler, will present at the 2019 Goldman Sachs Global Staples Forum at 2:00 PM EDT on Tuesday, May 14, 2019. Perrigo Company is dedicated to making lives better by bringing "Quality, Affordable Self-care Products™" that consumers trust everywhere they are sold.  The Company is a leading provider of over-the-counter health and wellness solutions that enhance individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed.  Visit Perrigo online at (http://www.perrigo.com).

  • Perrigo Increases Its Dividend By 11%
    PR Newswire

    Perrigo Increases Its Dividend By 11%

    TASE: PRGO), today announced that the company's Board of Directors, consistent with its recently approved strategic plan to evolve to a consumer self-care company, approved an 11% increase to the company's quarterly dividend to $0.21 per share from $0.19 per share. This dividend increase marks the 16th consecutive year Perrigo has increased its dividend. Perrigo Company is dedicated to making lives better by bringing "Quality, Affordable Self-care Products™" that consumers trust everywhere they are sold. The Company is a leading provider of over-the-counter health and wellness solutions that enhance individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed. Visit Perrigo online at (http://www.perrigo.com).

  • Perrigo To Host Investor Day
    PR Newswire

    Perrigo To Host Investor Day

    The event will feature presentations from Murray S. Kessler, President and Chief Executive Officer, as well as members of the Company's leadership team. Perrigo Company is dedicated to making lives better by bringing "Quality, Affordable Self-care Products™" that consumers trust everywhere they are sold.  The Company is a leading provider of over-the-counter health and wellness solutions that enhance individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed.  Visit Perrigo online at (http://www.perrigo.com). Certain statements in this press release are "forward-looking statements." These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements.

  • Perrigo Announces Tentative FDA Approval For The Generic Version Of Sernivo® Spray, 0.05%
    PR Newswire

    Perrigo Announces Tentative FDA Approval For The Generic Version Of Sernivo® Spray, 0.05%

    TASE: PRGO), a leading global provider of "Quality, Affordable, Self-Care Products™", today announced it has received tentative approval from the U.S. Food and Drug Administration for the generic version of Sernivo® (betamethasone dipropionate) Spray 0.05%. Perrigo previously settled its Hatch-Waxman litigation relating to Sernivo® (betamethasone dipropionate) Spray 0.05% brought by Promius Pharma LLC. Terms of the settlement remain confidential. Perrigo Executive Vice President and President Rx Pharmaceuticals Sharon Kochan stated, "Today's announcement marks our second tentative approval this year, in addition to four previously approved abbreviated new drug applications received in 2019.

  • Perrigo Announces Patent Litigation Settlement For The Generic Version Of Finacea® Foam, 15%
    PR Newswire

    Perrigo Announces Patent Litigation Settlement For The Generic Version Of Finacea® Foam, 15%

    Perrigo Executive Vice President and President Rx Pharmaceuticals Sharon Kochan stated, "This settlement is another example of our long-term commitment and investments in our extended topicals strategy. Perrigo Company is dedicated to making lives better by bringing high "Quality, Affordable Self-care Products™" that consumers trust everywhere they are sold.  The Company is a leading provider of over-the-counter health and wellness solutions that enhance individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed.  Visit Perrigo online at (http://www.perrigo.com). Certain statements in this press release are "forward-looking statements." These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements.

  • GlobeNewswire

    Sol-Gel Technologies Reports Full Year 2018 Financial Results and Provides Corporate Update

    Company met all milestones in 2018 and this year expects to report Phase III top-line results for Epsolay® and TWIN, potentially best-in-class papulopustular rosacea and acne.